The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
QINLOCK (Tudorrose Consulting Pty Ltd)
Product name
QINLOCK
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
123 working days (255)
Active ingredients
ripretinib
Registration type
NCE/NBE
Indication
QINLOCK (tablet) is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumours (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.